Welcome to our dedicated page for CV SCIENCES news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on CV SCIENCES stock.
CV Sciences, Inc. (CVSI) is a consumer wellness company dedicated to improving health through the integration of science and nature. Specializing in hemp extracts and science-backed natural ingredients, CV Sciences offers a range of products such as hemp extracts, softgels, and plant-based foods. The company's commitment to consumer well-being is evident in its mission to make healthy people healthier. With a focus on research-supported, plant-based alternatives, CV Sciences aims to provide high-quality products that cater to the well-being of both humans and pets. The recent launch of +PlusCBD™ Pet wellness treats, including the Pet Hip and Joint Health Chews and Pet Calming Care Chews, showcases CV Sciences' dedication to innovation and safety, validated by the National Animal Supplement Council (NASC). These premium CBD-infused chews, designed to support pet health, are crafted using organic hemp-derived CBD and a blend of antioxidants, anti-inflammatory agents, and essential supplements. The safety, efficacy, and quality of each product are ensured through rigorous testing by independent laboratories, aligning with NASC's stringent standards.
CV Sciences' strategic acquisitions, such as Elevated Softgels, further enhance its operational capabilities, allowing for in-house manufacturing and new product development. By leveraging Elevated Softgels' manufacturing expertise, CV Sciences aims to streamline production, increase operational efficiency, and expand its product offerings. The company's financial performance reflects its resilience and growth trajectory, with sequential revenue increases, improved gross margins, and strategic investments driving long-term value creation. As CV Sciences continues to innovate and expand its product portfolio, it remains committed to delivering science-backed, plant-based solutions that promote holistic well-being.
CV Sciences (OTCQB:CVSI) will release its third-quarter financial results on November 15, 2021, before the stock market opens. A conference call with investors is scheduled for 7:00 a.m. PT that same day, available via webcast on the company's Investor Relations website. CV Sciences operates in two segments: consumer products, focusing on hemp-derived CBD supplements, and drug development for CBD-based therapeutics. PlusCBD™ products are sold in over 7,700 U.S. retail locations, making it a leading CBD brand.
CV Sciences is pleased to announce the passage of California's AB 45, permitting the retail sale of hemp-derived extracts like CBD. This new law is expected to enhance the distribution of CV Sciences’ PlusCBD™ products within California, expanding access for consumers seeking health benefits. CEO Joseph Dowling expressed optimism that this legislation will serve as a responsible model for other states. With over 7,300 retail locations across the U.S., CV Sciences aims to leverage this opportunity to grow its market presence.
CV Sciences reported its financial results for Q2 2021, revealing revenue of $5.1 million, down from $5.4 million in Q2 2020. Despite this revenue decline, the company saw an improvement in gross margin to 44.7%, up from 43.0% year-over-year. The total cash balance decreased to $3.0 million from $4.5 million at year-end. The company expanded its retail presence to over 7,800 stores. Despite challenges from market competition and regulatory uncertainties, CV Sciences launched new products and reported a reduced operating loss of $3.5 million.
CV Sciences (OTCQB:CVSI) announced it will release its second-quarter financial results on August 12, 2021, after market close. A conference call for investors is scheduled the same day at 1:30 PM PT. The call will be accessible via the company's Investor Relations webpage and will be archived for 30 days. CV Sciences operates two divisions: a consumer product segment focused on CBD products and a drug development segment for CBD-based therapeutics. Its PlusCBD™ brand is recognized as a leader in the natural products market.
CV Sciences, Inc. (OTCQB:CVSI) announced that its CV™ Defense product received the 2021 Product of the Year: Immune Support Award from NutraIngredients-USA. This award recognizes innovation in nutrition and dietary supplements. CV™ Defense contains ingredients like PEA, reishi mushroom extract, vitamins A and D, selenium, and zinc, aimed at enhancing immune health. The award underscores the company's commitment to expanding its product portfolio beyond CBD, reflecting strong initial sales and consumer demand for effective wellness products.
CV Sciences announced progress in developing a CBD-based pharmaceutical for nicotine addiction in collaboration with UC San Diego. A preclinical study revealed that chronic CBD treatment significantly reduced withdrawal symptoms in nicotine-dependent rats. This research highlights CV Sciences' commitment to addressing the $2 billion smokeless tobacco addiction market, with potential FDA-approved treatment in development. The company has secured a patent for a proprietary CBD and nicotine formulation, further expanding its product development opportunities.
CV Sciences (CVSI) reported Q1 2021 revenue of $4.8 million, a 41% decrease from $8.3 million in Q1 2020, attributed to the ongoing COVID-19 pandemic and increased market competition. Despite this, the gross margin slightly improved to 48.7% from 48.5% year-over-year. The company’s cash balance rose to $5.7 million, up from $4.5 million at year-end. Retail distribution expanded to over 7,300 stores, up from 5,799 a year prior. New product launches, including ProCBD™ and PlusCBD™ Calm and Sleep gummies, were well received, indicating potential future growth.
CV Sciences has launched new PlusCBD™ Calm and Sleep gummies aimed at supporting healthy stress responses and sleep cycles. Each gummy contains 10mg of CBD, plus 5-HTP and L-Theanine for Calm, and melatonin, magnolia bark, and lemon balm for Sleep. These products promise no artificial additives and are third-party tested for quality. CV Sciences emphasizes its commitment to scientifically formulated products backed by clinical research, available for purchase online and in retail later this year.
CV Sciences (OTCQB:CVSI) will announce its financial results for Q1 2021 on May 13, 2021, after market close. A conference call to discuss these results is scheduled for 1:30 PM PT (4:30 PM ET) on the same day. Access to the call will be available through the Company’s Investor Relations webpage, with a replay offered two hours post-call until May 20, 2021. CV Sciences operates in two sectors: consumer products and drug development, with its PlusCBD™ products leading the hemp-derived CBD market across over 7,300 retail locations in the U.S.
CV Sciences (OTCQB: CVSI) has announced a partnership with Alkemist Labs to support the National Institute of Standards and Technology (NIST) in enhancing cannabis testing methodologies. This collaboration aims to improve measurement accuracy for cannabis products, crucial for legal and safety claims. CV Sciences will provide hemp oil samples for testing, and Alkemist Labs will measure cannabinoid levels. NIST’s Canna Quality Assurance Program (CannaQAP) will benefit various laboratories and researchers in the cannabis industry.
FAQ
What is the current stock price of CV SCIENCES (CVSI)?
What is the market cap of CV SCIENCES (CVSI)?
What products does CV Sciences offer?
What are some recent innovations by CV Sciences?
How does CV Sciences ensure product quality and safety?
What strategic acquisitions has CV Sciences made recently?
What is CV Sciences' approach to innovation and growth?
